ÂÜÀòÂÒÂ×

Kevin N. Heller is an accomplished professional in the biopharmaceutical field, currently serving as an Investment Team Advisor at Ausangate Capital and an Executive in Residence at BioHealth Innovation, Inc., where assistance is provided to biotech entrepreneurs. Heller has held significant roles in various organizations, including Chief Medical Officer at Tallac Therapeutics and NextCure, Inc., and Executive Vice President of Research and Development at Jasper Therapeutics. Heller's extensive experience includes leadership positions at major pharmaceutical companies such as Incyte, AstraZeneca, and Bristol-Myers Squibb, focusing on oncology and immuno-oncology. Heller also contributes to the Society for Science as a Board Member on the National Leadership Council and has served as an Adjunct Professor at Yale University School of Medicine. Heller holds a Bachelor of Science in Molecular Biophysics and Biochemistry from Yale University and an MD from The George Washington University School of Medicine and Health Sciences.